(CercleFinance.com) – AstraZeneca announces positive results from a pivotal phase III trial showing that danicopan, in addition to standard C5 inhibitor treatment, Ultomiris (ravulizumab) or Soliris (eculizumab) continued to demonstrate clinical benefit in patients with paroxysmal nocturnal hemoglobinuria (PNH) who have clinically significant extravascular hemolysis (EVH).
Data showed that improvements in mean hemoglobin levels and absolute reticulocyte counts (ARC), demonstrated after 12 weeks, were maintained through 48 weeks.
PNH is a rare blood disorder that can cause thrombosis (blood clots) and lead to organ damage and potentially premature death.
“These new data further demonstrate the potential of danicopan as an adjunct to Ultomiris or Soliris to address the needs of a small subset of PNH patients with clinically significant VTE,” commented Austin Kulasekararaj, hematologist. consultant at King’s College Hospital, London, and researcher in the trial.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
